SK bioscience Co.,Ltd. (302440.KS)

KRW 37300.0

(-0.93%)

Market Cap (In KRW)

2922.35 Billion

Revenue (In KRW)

369.5 Billion

Net Income (In KRW)

22.31 Billion

Avg. Volume

183.66 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
43650.0-73700.0
PE
-
EPS
-
Beta Value
1.178
ISIN
KR7302440003
CUSIP
-
CIK
-
Shares
78347300.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jae-Yong Ahn
Employee Count
-
Website
https://www.skbioscience.co.kr
Ipo Date
2021-03-18
Details
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.